cadisegliatin — Topline data
mid 2027
An overview of the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in T1D with topline data expected in mid 2027Source filing
VTVT biotech catalysts & pipeline
VTV THERAPEUTICS INC · Data as of 2026-10-25